FGF19 and hepatocellular carcinoma: There is growing evidence that the FGFR4 pathway may contribute to the development of hepatocellular carcinoma (HCC) [9, 10], and selective FGFR4 inhibitors have shown remarkable anti-tumor activity in HCC xenografts harboring FGF19-overexpression.